ovarian cancer

Immunotherapeutic approaches to ovarian cancer treatment

By Late Holbrook Kohrt et. al. (2015.03.24)
Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA

OvaCure's co-founder, Late Associate Professor Holbrook Kohrt

OvaCure's co-founder, Late Associate Professor Holbrook Kohrt

Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have been developed. 

Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.